Status:
UNKNOWN
Inflammatory Regulation Effect of NAC on COVID-19 Treatment
Lead Sponsor:
Dr. Tariq Alhawassi
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Study times to evaluate the efficacy of N-Acetylcysteine therapy in the management of adult admitted patients with COVID-19.
Eligibility Criteria
Inclusion
- Adult above 18 years of age
- Admitted to the hospital With confirmed COVID-19 by RT-PCR test
- On oxygen supplement
Exclusion
- Active use of NAC
- Known NAC allergy
- In the opinion of the treating team, progression of death is imminent and inevitable within the next 24 hour, irrespective of provision treatment
- All patients enrolled in any other investigational drug studies in COVID-19.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2021
Estimated Enrollment :
1180 Patients enrolled
Trial Details
Trial ID
NCT04455243
Start Date
August 1 2020
End Date
August 30 2021
Last Update
July 21 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.